Showing results (491-500 of 506) with videos related to

Sort By:
Pageof 51
Nature Communications|November 6, 2022
Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood EpendymomasSibo Zhao, Jia Li, Huiyuan Zhang, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, et al.
Gut|February 10, 2026
SDC1+ CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancersGuan-Feng Gao, Zhao-Hui Ruan, Shi-Bo Zhang, et al.
Nature Communications|April 29, 2022
Comprehensive profiling of 1015 patients' exomes reveals genomic-clinical associations in colorectal cancerQi Zhao, Feng Wang, Yan-Xing Chen, et al.
Plos Medicine|May 10, 2024
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trialDe-Shen Wang, Chao Ren, Shan-Shan Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2021
Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical TrialHui Chen, Gang Nan, Ding Wei, et al.
Annals of Surgery|November 3, 2025
Association of Recurrence with a Tumor-informed Personalized ctDNA Detection Approach in Resectable Colorectal Cancer: Results of a Prospective Observational StudyDi Cao, Guang-Zhao Lv, Cong Li, et al.
International Journal of Cancer|December 7, 2018
Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular featuresWu Jiang, Mu-Yan Cai, Shi-Yong Li, et al.
European Radiology|April 6, 2022
Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolizationDongdong Xia, Qiuhe Wang, Wei Bai, et al.
Eclinicalmedicine|February 18, 2026
Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation studyJian-Jian Chen, Zhi-Cheng Jin, Jia-Wei Zhou, et al.
Pageof 51